Organon & Co. Common Stock OGN 深 沪
等待开盘 12-01 09:30:00 美东时间
7.71
-0.030
-0.39%
华盛通- 最 高7.85
- 今 开7.77
- 成交量 195.04万股
- 最 低 7.665
- 昨 收 7.74
- 总市值 20.05亿
- 52周最高 16.89
- 市盈率 静 2.31
- 换手率 0.75%
- 52周最低 6.16
- 委 比 5.88%
- 总股本 2.60亿
- 历史最高 36.055
- 量 比 0.38
- 振 幅 2.39%
- 历史最低 6.16
- 每 手 1
- 风险率 2.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多复星医药子公司复宏汉霖与Organon共同宣布美国首个帕妥珠单抗生物类似药POHERDY获美国FDA批准
（来源：复星医药） 转自：复星医药 中国上海 & 美国新泽西州泽西市，2025年11月17日 —— 复星医药子公司复宏汉霖（2696.HK）与O...
11-17 18:51
The FDA Has Approved Shanghai Henlius Biotech And Organon's Partnered Biologics License Application For Poherdy, An Interchangeable Biosimilar To Perjeta (Pertuzumab), For All Indications Of The Reference Product
POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic therapies for patients with certain
11-17 18:32
复宏汉霖(02696.HK)POHERDY(帕妥珠单抗)的生物制品许可申请获美国FDA批准
【财华社讯】复宏汉霖(02696.HK)公布，集团收到美国食品药品管理局(“FDA”)的批准函，POHERDY®(帕妥珠单抗)420mg/14mL(30mg/...
11-14 17:12
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
复宏汉霖宣布地舒单抗BILDYOS和BILPREVDA获英国批准上市
中国上海，2025年11月11日——复宏汉霖（2696.HK）宣布，英国药品和健康产品管理局（MHRA）已批准地舒单抗注射液（60 mg/mL）BILDYOS...
11-11 17:32
Organon lowers 2025 revenue guidance to $6.2B–$6.25B amid U.S. Nexplanon headwinds and Jada divestiture
Earnings Call Insights: Organon & Co. (OGN) Q3 2025 Management View Carrie Cox announced her transition to Executive Chair, taking a more active management role following the Board’s investigation int...
11-10 23:52
Organon Cuts 2025 Sales Outlook Despite Earnings Beat
Organon posts Q3 EPS of $1.01, topping estimates, trims 2025 sales outlook, and highlights positive Vtama data in children with atopic dermatitis.
11-10 23:05
Organon declares $0.02 dividend
Organon (OGN) declares $0.02/share quarterly dividend, in line with previous. Forward yield 1.08% Payable Dec. 11; for shareholders of record Nov. 20; ex-div Nov. 20. See OGN Dividend Scorecard, Yield...
11-10 22:49
Earnings Snapshot: Organon tops Q3 estimates; lowers FY25 revenue outlook
Seeking Alpha (Seeking Alpha) More on Organon Organon: Critical Assessment Of The Audit Committee Investigation Results The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products Orga...
11-10 21:12
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
